Drugs / PF-06940434
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04152018 | Nov 2019 → Dec 2024 | bile duct cancer, endometrial cancer, esophageal cancer, gastric cancer +7 | Pfizer | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06940434 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04152018 ↗ |
| Action | Inhibit | “Integrin alpha-V/beta-8 Antagonist” NCT04152018 ↗ |
| Route | Intravenous | “given intravenously (IV)” NCT04152018 ↗ |